Tough DF

References (1)

Title : Phase 1 and pre-clinical profiling of ESM-HDAC391, a myeloid-targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia - Furze_2022_Br.J.Clin.Pharmacol__

Author(s) : Furze RC , Molnar J , Parr NJ , Ahmad F , Henry Y , Howe D , Singh R , Toal M , Bassil AK , Bernard SG , Davis RP , Gibson A , Maller NC , Sharp C , Tough DF , Prinjha RK , Lewis HD

Ref : British Journal of Clinical Pharmacology , : , 2022

Abstract :

PubMedSearch : Furze_2022_Br.J.Clin.Pharmacol__

PubMedID: 35655123

Tough DF

References (1)

1. Phase 1 and pre-clinical profiling of ESM-HDAC391, a myeloid-targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia - Furze_2022_Br.J.Clin.Pharmacol__